Trial reportJHEP reports : innovation in hepatology2026
Advanced extrahepatic cholangiocarcinoma and gallbladder cancer: Post-hoc analysis of the ABC-01, -02 and -03 clinical trials.
Trial report in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Gemcitabine, Alone or in Combination With Cisplatin, in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumors: A Multicentre, Randomized Phase III Study
Randomised Phase II Trial of Cediranib (AZD2171) Versus Placebo in Addition to Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsPrevious data suggest that patients with intrahepatic cholangiocarcinoma (iCCA) have a better prognosis compared with those with other biliary tract cancers (BTC). However, granularity on outcomes for advanced extrahepatic cholangiocarcinoma (eCCA) (including distal- [dCCA] and perihilar cholangiocarcinoma [pCCA]) and gallbladder cancer (GBC) is lacking. With targeted therapies being developed for these subgroups, benchmark data are of value to understand the natural history and inform future trial design.
methodsThe aim of this post hoc analysis was to provide reference survival data for patients with advanced eCCA treated with first-line cisplatin-gemcitabine (CisGem) chemotherapy within the prospective, randomised Advanced Biliary tract Cancer (ABC)-01, -02, and -03 studies. Individual-level data from patients with eCCA and GBC recruited to these studies were retrieved. Survival analysis was performed using Kaplan-Meier and univariate and multivariable Cox regression. Logistic regression was utilised whenever required.
resultsOf 534 patients recruited into the ABC-01, -02, and -03 studies, eligible patients for this analysis included a total of 117 eCCA treated with CisGem (including 68 with pCCA and 49 with dCCA) and 112 with GBC. Patients with pCCA had less previous surgery (4.08%) and the highest rate of biliary stenting (26.53%). Patients with dCCA were predominantly metastatic at study entry (77.94%), while those with pCCA had a rate of 40.82% and 59.18% for locally advanced and metastatic disease at study entry, respectively. Most patients in the GBC cohort were women (62.50%) and predominantly metastatic (81.25%). Estimated median overall survival (OS) for dCCA was 14.25 months (95% CI: 8.80-17.44) and 12.18 months (95% CI: 8.31-16.12) for pCCA. Estimated median progression-free survival (PFS) was 8.28 months (95% CI: 6.31-9.39) for dCCA and 8.37 months (95% CI: 6.53-10.61) for pCCA. PFS and OS for GBC were 6.86 months (95% CI: 5.75-8.51) and 10.84 months (95% CI: 8.97-12.41), respectively. Objective radiological response was 23.93% for eCCA: (dCCA [27.94%] and pCCA [18.37%]) and 26.79% for the GBC cohort. Prognostic factors of interest for OS included performance status (PS) and CA125 for eCCA, and grade of differentiation for GBC. For OS in iCCA, dCCA, pCCA, and GBC, multivariable analysis confirmed that patients with GBC had the shortest OS (hazard ratio 2.01 [95% CI: 1.18-3.43]; p value 0.011 [vs. iCCA]) when adjusted for other prognostic factors (PS, stage, and tumour markers).
conclusionsWithin the BTC subgroups, GBC had the worse survival. PS and baseline tumour markers (CA125 and CEA) were strongly associated with worse survival. These subgroup data provide a reference for future studies incorporating immunotherapy and other new treatment strategies for BTCs. IMPACT AND IMPLICATIONS: The data presented here provide benchmark outcome data for subgroups of patients with eCCA and GBC treated with CisGem for future clinical trial design. Despite the absence of immunotherapy, the lack of alternative comprehensive series highlights the value of the current series. The data presented here could be utilised for interpretation of current studies and design of future trials, by providing outcome data for main BTC subgroups of interest. CLINICAL TRIAL REGISTRATION NUMBERS: ABC-01/ABC-02 (NCT00262769), ABC-03 (NCT00939848).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.